AJP Asia Intelligence Agency

U.S. rejects China's breakout cancer drug

SEOUL, November 16 (AJP) — The U.S. Food and Drug Administration (FDA) has rejected ivonescimab, a lung cancer drug invented by China’s Akeso, setting back a medicine that had become the leading example of China’s rise as a source of new drugs.

Summit Therapeutics, the Miami-based company that bought the drug’s U.S. rights from Hong Kong-listed Akeso, disclosed the decision on Sunday. The agency found that ivonescimab slowed the cancer’s progression in a global late-stage trial but did not show a statistically significant survival benefit, and extra analyses Summit filed afterward did not change regulators’ minds.

The rejection applies only to a narrow group of patients with advanced lung cancer whose earlier targeted therapy had stopped working. Attention now turns to a trial pitting the drug against Merck’s Keytruda in patients who have not yet been treated, which is expected to report results by year-end. Co-chief executive Bob Duggan said “nothing changes” in Summit’s belief in the drug.

AJP Takeaways

  • The U.S. Food and Drug Administration rejected ivonescimab, invented by China’s Akeso, because it did not show a statistically significant survival benefit, even though it slowed cancer progression.
  • The decision covers only a narrow group of advanced lung cancer patients whose earlier targeted therapy had stopped working.
  • Attention now turns to a trial against Merck’s Keytruda in patients who have not yet been treated.

Tags: Summit Therapeutics, Akeso, U.S. Food and Drug Administration, FDA, ivonescimab, Keytruda, Merck, Bob Duggan, lung cancer, China biotech